Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Free Cash Flow (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Free Cash Flow readings, the most recent being -$9.9 million for Q4 2023.

  • On a quarterly basis, Free Cash Flow fell 34.24% to -$9.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$32.8 million, a 43.48% decrease, with the full-year FY2025 number at -$37.0 million, up 0.5% from a year prior.
  • Free Cash Flow hit -$9.9 million in Q4 2023 for Elicio Therapeutics, down from -$5.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $20.6 million in Q4 2020 to a low of -$21.9 million in Q3 2020.
  • Median Free Cash Flow over the past 4 years was -$9.7 million (2023), compared with a mean of -$8.2 million.
  • Biggest five-year swings in Free Cash Flow: soared 151.76% in 2022 and later tumbled 269.97% in 2023.
  • Elicio Therapeutics' Free Cash Flow stood at $20.6 million in 2020, then tumbled by 168.1% to -$14.0 million in 2021, then skyrocketed by 47.43% to -$7.4 million in 2022, then tumbled by 34.24% to -$9.9 million in 2023.
  • The last three reported values for Free Cash Flow were -$9.9 million (Q4 2023), -$5.2 million (Q3 2023), and -$9.5 million (Q2 2023) per Business Quant data.